Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
about
The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseasesModulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modificationsTargeting host factors: A novel rationale for the management of hepatitis C virusPhytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterationsCB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptorsAnticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment.Targeted deletion of PTEN in cardiomyocytes renders cardiac contractile dysfunction through interruption of Pink1-AMPK signaling and autophagyEnergy intake and adiponectin gene expression.Fermented wheat germ extract (avemar) in the treatment of cardiac remodeling and metabolic symptoms in rats.Antilipogenic and anti-inflammatory activities of Codonopsis lanceolata in mice hepatic tissues after chronic ethanol feedingPPARα Protein Expression Was Increased by Four Weeks of Intermittent Hypoxic Training via AMPKα2-Dependent Manner in Mouse Skeletal MuscleInhibition of gluconeogenic genes by calcium-regulated heat-stable protein 1 via repression of peroxisome proliferator-activated receptor α.Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.New treatments for chronic hepatitis C.Microvascular responsiveness in obesity: implications for therapeutic intervention.Long-term effects of placental growth on overweight and body composition.Advanced Glycation End Products (AGE) Potently Induce Autophagy through Activation of RAF Protein Kinase and Nuclear Factor κB (NF-κB).Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndromePeroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistanceManagement of the metabolic syndrome and type 2 diabetes through lifestyle modification.Adiponectin: a key adipokine in alcoholic fatty liver.Mechanisms of coronary microvascular adaptation to obesity.PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.Novel pathways and therapies in experimental diabetic atherosclerosis.Endometrial abnormality in women with polycystic ovary syndrome.Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease.Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging.Peroxisome proliferator-activated receptors and hepatitis C virusPPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.Creatine supplementation as a possible new therapeutic approach for fatty liver disease: early findings.Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review.Cardiovascular consequences of metabolic syndrome.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.Recent Advances in Nanoparticle-Mediated Delivery of Anti-Inflammatory PhytocompoundsFine metabolic regulation in ruminants via nutrient-gene interactions: saturated long-chain fatty acids increase expression of genes involved in lipid metabolism and immune response partly through PPAR-α activation.PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?Interaction Between Peroxisome Proliferator Activated Receptor δ and Epithelial Membrane Protein 2 Polymorphisms Influences HDL-C Levels in the Chinese Population.Benzoxazinones as Human Peroxisome Proliferator Activated Receptor Gamma (PPARγ) Agonists: A Docking Study Using Glide.Effects of a wide range of dietary nicotinamide riboside (NR) concentrations on metabolic flexibility and white adipose tissue (WAT) of mice fed a mildly obesogenic diet.
P2860
Q24612698-A53B3BEB-18BE-4127-8BA8-B4E4E096A5FCQ27015807-4FC0E5A0-D131-46EB-A984-AF85026E6733Q27488999-44A6E62E-A7ED-4573-99F9-92326400834BQ28484781-DD7CE70E-4585-4D27-BCBC-B7C88E1B4224Q28610813-BBA13D7B-65A4-40CC-BB16-F4D46B3E340DQ33692555-8EE141EB-8158-4AA3-A133-DD6942F2648FQ34100538-93FB206E-0776-4756-B42E-EB5ABAAB9D7CQ34778935-DF63C7EC-B54B-40DF-AE77-97ADDA03A68FQ34979370-62449FDE-E593-490B-A9FC-C56E04402545Q35103679-5862F85E-70A4-47A8-8FFA-17E950837BDAQ35370819-260D576E-E52F-4C34-9911-37BC5471E28FQ35553487-75D40823-48AC-4104-A38B-67DF0E009C7FQ35562621-5EE18B03-F0A0-4081-AF59-2535B2158E55Q35636191-8B8C4F08-A467-42BC-96AD-ABC12EDF007CQ35833006-F288E222-8933-40ED-A0F5-8A0231355BC4Q35859728-393B7248-B153-4652-BDDB-02A4FBD002F3Q35915419-6781DD70-6ED7-400B-A89C-8FA7BBA235D2Q36466224-DA4F3F4C-0868-4B6A-BFD1-70F94D9560E2Q36970120-45227D72-E70E-4770-B59C-104438CEECAAQ37037509-165024BF-D774-4CE8-9107-36F0E7B67849Q37463193-C7973BCA-7E9D-491B-A1C9-5F4DCA823629Q37505809-47DB1B12-38A4-4E41-A8DC-090339D48807Q37522921-BC2AE211-FB74-43B7-970B-096D1B0608A2Q37616202-3C9AD658-7F85-4253-9072-DB6634021B91Q37990618-C830EF31-0E16-48B4-BD3F-CA1ED47DD690Q38005532-0DE47085-53F0-4CCF-8F2E-65801A7857D8Q38097092-9DF24E9E-0BC3-46D2-9893-6AFFAD1736C7Q38402537-A2F455B0-D9FF-48E3-8A56-472AB2450F35Q38633502-BA2E6177-01D7-480A-AA3D-4B95097875A3Q38674739-777AF661-863D-4608-8716-2B880D0ABDB9Q38718576-5C46345C-2F7E-4150-ACCC-A70635F07EABQ38834116-B490F4D5-3005-4861-AF07-5C267CF1F966Q39106973-5C26C963-31E7-4F59-A522-53BE2BCA89EAQ39200940-4AE2BC39-AE41-4328-98B6-BD491C1FA5BEQ39204729-79FC334B-E9C0-49AB-95F7-B8D1184553E5Q39512590-8BC1B81C-0610-48CE-98A5-A7B0ECF45967Q39740098-8668EB11-342E-481B-8BDC-0166D9AB73EAQ40619869-A6B0BFDC-B788-4779-A254-093841014E63Q40695748-4592937F-6CF6-407F-8085-3FC34BCB41B5Q41540768-0645F299-0CEA-4F3A-A1FC-F9DD7EB3F54A
P2860
Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Peroxisome proliferator-activa ...... and type 2 diabetes mellitus.
@en
type
label
Peroxisome proliferator-activa ...... and type 2 diabetes mellitus.
@en
prefLabel
Peroxisome proliferator-activa ...... and type 2 diabetes mellitus.
@en
P1476
Peroxisome proliferator-activa ...... and type 2 diabetes mellitus.
@en
P2093
P356
10.2174/157339907779802067
P577
2007-02-01T00:00:00Z